A bioequivalence study of two levofloxacin tablets in healthy male subjects
Translational and Clinical Pharmacology
;
: 102-105, 2014.
Article
in English
| WPRIM
| ID: wpr-165849
ABSTRACT
Levofloxacin is a bactericidal broad spectrum antibiotic against Gram-positive and Gram-negative pathogens. A randomized, two-treatment, two-period, two-way crossover study was conducted to evaluate the bioequivalence of Lectacin 250 mg tablet, a generic levofloxacin, to its reference drug, Cravit 250 mg tablet. Each period was separated by a 7-day washout. Serial blood samples were collected until 24 h after dosing and plasma levofloxacin concentrations were determined using a high performance liquid chromatography. Pharmacokinetic parameters were analyzed using K-BE Test 2007 and BA calc 2007 (Ministry of Food and Drug Safety, Cheongju-si, South Korea). The peak concentration (Cmax) and the area under the plasma concentration versus time curve from 0 to the last measurable concentration (AUC(0-t)) for the generic and reference levofloxacin were 4.48+/-0.89 mg/L and 4.46+/- 0.95 mg/L, and 25.33+/-4.12 mg*h/L and 25.77+/-4.01 mg*h/L, respectively, leading to a geometric mean ratio (90% confidence interval) of the generic to the reference levofloxacin of 1.0060 (0.9339-1.0842) and 0.9810 (0.9476-1.0159), respectively, for Cmax and AUC(0-t). Lectacin 250 mg tablet is bioequivalent to Cravit 250 mg tablet.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Plasma
/
Tablets
/
Pharmacokinetics
/
Therapeutic Equivalency
/
Chromatography, Liquid
/
Cross-Over Studies
/
Levofloxacin
Type of study:
Controlled clinical trial
Limits:
Humans
/
Male
Language:
English
Journal:
Translational and Clinical Pharmacology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS